GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Chronic kidney disease (CKD): It is the gradual loss of ... Stage 3: Divided into 3a and 3b. Symptoms start at this stage. Stage 3a: eGFR between 45 and 59ml/min Stage 3b: eGFR between 30 and ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Lithium is associated with an increased risk for thyroid dysfunction and chronic kidney disease (CKD) in patients with ...

People with kidney disease may be at higher risk of anxiety and depression. But taking care of your mental health can have a positive effect on your outlook with kidney disease. Chronic kidney ...

Efficacy was established based on the time to first occurrence of a primary composite endpoint event, defined as onset of persistent 50% or greater reduction in eGFR according to the Chronic Kidney ...

In most cases, chronic kidney failure can't be ... kidney disease 45–59% of normal capacity Stage 3b 30–44 Moderate to severe kidney disease 30–44% of normal capacity Stage 4 15–29 Severe ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of kidney disease worsening, kidney failure and cardiovascular disease (CVD) ...